Skip to main content

Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer.

Publication ,  Journal Article
Witkiewicz, A; Ryder, A; Neilson, LM; Utama, FE; Tran, TH; Hyslop, T; Rui, H
Published in: J Clin Oncol
May 20, 2008

22071 Background: We have previously reported that presence of nuclear localized, tyrosine phosphorylated Stat5 in breast carcinoma cells is associated with a highly favorable prognosis in a material of 209 patients with node-negative breast cancer. This initial analysis was performed on tissue array sections and not on whole sections. Furthermore, the initial study did not distinguish between Stat5a and Stat5b, since the phosphotyrosine-motif recognized by the antibody is the same in Stat5a and Stat5b. Stat5a and Stat5b are highly homologous transcription factors with overlapping but distinct regulation and biological effects. It has remained unclear whether both Stat5a and Stat5b contribute to the favorable prognosis associated with positive anti-phospho-Stat5 status. METHODS: We have now performed a retrospective follow-up analysis of nuclear localized, tyrosine phosphorylated Stat5 in whole sections of breast cancer from an independent material of 400 node-negative breast cancer specimens with outcome data provided by the National Cancer Institute's Cooperative Breast Cancer Tissue Resource (CBCTR). We also analyzed levels of Stat5a and Stat5b individually and performed survival analyses. RESULTS: Nuclear localized, tyrosine phosphorylated Stat5 remained a significant favorable prognostic marker in this independent follow-up material of human breast cancer, validating our previous data. Furthermore, nuclear localized Stat5a and Stat5b both correlated with favorable prognosis. In contrast, nuclear localized phosphorylated Stat3 did not significantly correlate with prognosis. CONCLUSIONS: Levels of nuclear localized, tyrosine phosphorylated Stat5a/b, alone or in conjunction with levels of nuclear Stat5a or Stat5b proteins, could be a cost-effective test identifying a subset of node-negative breast cancer patients with excellent prognosis who may be managed less aggressively following surgery. No significant financial relationships to disclose.

Duke Scholars

Published In

J Clin Oncol

EISSN

1527-7755

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

22071

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Witkiewicz, A., Ryder, A., Neilson, L. M., Utama, F. E., Tran, T. H., Hyslop, T., & Rui, H. (2008). Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer. J Clin Oncol, 26(15_suppl), 22071.
Witkiewicz, A., A. Ryder, L. M. Neilson, F. E. Utama, T. H. Tran, T. Hyslop, and H. Rui. “Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer.J Clin Oncol 26, no. 15_suppl (May 20, 2008): 22071.
Witkiewicz A, Ryder A, Neilson LM, Utama FE, Tran TH, Hyslop T, et al. Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer. J Clin Oncol. 2008 May 20;26(15_suppl):22071.
Witkiewicz, A., et al. “Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer.J Clin Oncol, vol. 26, no. 15_suppl, May 2008, p. 22071.
Witkiewicz A, Ryder A, Neilson LM, Utama FE, Tran TH, Hyslop T, Rui H. Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer. J Clin Oncol. 2008 May 20;26(15_suppl):22071.

Published In

J Clin Oncol

EISSN

1527-7755

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

22071

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences